Scientists have discovered a new type of immune defense in E. coli bacteria that turns viral infection machinery against the ...

(NASDAQ: REGN) today announced that the European Commission (EC) has granted conditional marketing approval of Lynozyfic™ (linvoseltamab) to treat adults with relapsed and refractory (R/R) multiple ...

The findings indicate that the Cel System supplement range may effectively lower biological age and enhance health metrics, ...